Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.50 |
| ▸ | ACACA | Q13085 | 3/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31081572 | 0.88 | CXCR2 (0.50) | MAOBEGFRMEN1PABPC1KMT2A | |
| SCHEMBL6348703 | 0.87 | PPARG (0.42) | OPRM1OPRD1OPRK1MAOBEGFR | |
| SCHEMBL6338944 | 0.87 | FFAR4 (0.43) | OPRM1OPRD1OPRK1KMT2A | |
| SCHEMBL1034311 | 0.85 | MAOB (0.63) | MAOBEGFRMEN1KMT2ANR4A1 | |
| SCHEMBL6339006 | 0.83 | OPRM1 (0.57) | ACACBACACAOPRM1OPRD1OPRK1 | |
| SCHEMBL6346472 | 0.83 | MAOB (0.69) | ACACBACACAOPRM1OPRD1OPRK1 | |
| SCHEMBL6339254 | 0.83 | NR4A2 (0.68) | ACACBACACAOPRM1OPRD1OPRK1 | |
| SCHEMBL6703917 | 0.82 | NR4A2 (0.70) | MAOBEGFRNR4A1NR4A2NR4A3 | |
| SCHEMBL6350325 | 0.81 | MAOB (0.47) | MAOBEGFRNR4A1NR4A2NR4A3 | |
| SCHEMBL6347635 | 0.77 | MAOB (0.59) | ACACBACACAOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890932-B2 | Immunoglobulin e antibody suppressors | TEIJIN LIMITED (JP) | 2005-05-10 | — | — | US | disclosed |
| EP-1101755-B1 | ANTHRANILIC ACID DERIVATIVES | TEIJIN LTD (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20030232811-A1 | Immunoglobulin e antibody suppressors | TEIJIN LIMITED | 2003-12-18 | — | — | US | disclosed |
| US-6649656-B1 | Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents | TEIJIN LIMITED (JP) | 2003-11-18 | — | — | US | disclosed |
| EP-1101755-A1 | ANTHRANILIC ACID DERIVATIVES | TEIJIN LIMITED (JP) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232811-A1 | Immunoglobulin e antibody suppressors | IGLV6-57, FCGRT, IGSF11 | ACACB 1367/4885ACACA 1115/4885OPRM1 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.